This page follows Sofinnova Investments, Inc.’s institutional portfolio as disclosed in its quarterly Form 13F filings with the SEC. A Form 13F is a required filing for institutional investment managers overseeing more than $100 million in U.S. equities, and it offers a snapshot of long positions held at the end of each quarter — not the exact days trades were placed, and not a full picture of options, shorts, or non-U.S. holdings. We update this profile every quarter as new filings become public, so bookmark it if you want a running record of how Sofinnova’s book is shifting over time rather than a one-off headline.
During the quarter ending 2026-03-31, Sofinnova’s 13F showed a mix of fresh bets, larger stakes in existing holdings, and a notable round of exits, giving a picture of where the fund’s attention moved this period.
New and expanded positions
Sofinnova opened new positions in Biogen Inc (BIIB) worth $42,078,085 and AstraZeneca PLC (AZN) worth $89,938,434, alongside new stakes tied to broad index products: Invesco QQQ TR ($86,577,000), two separate iShares TR positions ($80,203,750 and $148,800,000), and SPDR Series Trust ($134,116,500). These fund-level additions sit alongside the single-stock names and may reflect portfolio management activity rather than a directional biotech thesis. On the existing-holdings side, several positions grew substantially: Ultragenyx Pharmaceutical Inc (RARE) rose 3,340% from $1,915,900 to $65,906,354, Axsome Therapeutics Inc. (AXSM) climbed 1,409% from $2,240,262 to $33,804,000, Bristol-Myers Squibb Co (BMY) increased 48% from $81,610,896 to $120,615,929, Insmed Inc (INSM) grew 107% from $27,289,646 to $56,590,184, and Alcon AG added 110%, moving from $26,205,901 to $55,003,390.
Positions exited
The filing also showed a long list of full exits during the quarter. Sofinnova closed out a prior AstraZeneca PLC (AZN) stake previously worth $150,060,465 — notable given the fund opened a separate, smaller AstraZeneca position in the same period. Other exits included Avidity Biosciences Inc ($53,745,217), Centessa Pharmaceuticals PLC ($27,617,893), Cidara Therapeutics Inc ($39,818,736), Glaukos Corp (GKOS) at $32,532,532, Intuitive Surgical Inc (ISRG) at $71,909,596, Eli Lilly & Co (LLY) at $66,256,171, Vertex Pharmaceuticals Inc at $74,620,336, and AbbVie Inc (ABBV) at $72,610,238. As with any 13F, these figures reflect reported quarter-end values and don’t capture the specific dates or prices behind each move.
Check back after the next quarterly filing window for updated position sizes, new entries, and further exits as they’re disclosed. This profile is intended purely as an informational reference on 13F activity, not a recommendation to buy, sell, or hold any of the securities mentioned.
Related ticker coverage
- BIIB — all coverage →
- AZN — all coverage →
- RARE — all coverage →
- AXSM — all coverage →
- BMY — all coverage →
- INSM — all coverage →
- GKOS — all coverage →
- ISRG — all coverage →
- LLY — all coverage →
- ABBV — all coverage →
Source: SEC Form 13F filings. This page updates every quarter.